NCT04127669View on ClinicalTrials.gov

Study Evaluating Efficacy and Safety of OSU6162 in the Treatment of Residual Symptoms After Stroke

PHASE2CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

March 20, 2017

Primary Completion Date

January 28, 2020

Study Completion Date

September 30, 2020

Conditions
Stroke Sequelae
Interventions
DRUG

OSU 6162

The active ingredient of OSU6162 is the S-enantiomer with the chemical name (S)-3-\[3-(methylsulfonyl)phenyl\]-1-propylpiperidine hydrochloride. The substance is a white powder with a melting point of 177-182°C. Solubility in water is \> 2000 mg/ml. Current laboratory code used is OSU6162-HCl. In trial protocol, OSU6162-HCl is shortened to OSU6162.

DRUG

Placebo oral tablet

Circular coated tablet (with identical appearance to active treatment tablets 15 mg).

Trial Locations (1)

SE-43137

Gottfries Clinic AB, Gothenburg

All Listed Sponsors
collaborator

Gottfries Clinic AB

UNKNOWN

lead

Arvid Carlsson Research AB

INDUSTRY

NCT04127669 - Study Evaluating Efficacy and Safety of OSU6162 in the Treatment of Residual Symptoms After Stroke | Biotech Hunter | Biotech Hunter